De Novo Truncating Variants in ASXL2 Are Associated with a Unique and Recognizable Clinical PhenotypeVandana Shashi, Jennifer E. Posey, Loren D.M. Peña et al.|The American Journal of Human Genetics|2016Cited by 87
Looking beyond the exome: a phenotype-first approach to molecular diagnostic resolution in rare and undiagnosed diseasesLoren D.M. Peña, Lorraine Potocki, Yong‐Hui Jiang et al.|Genetics in Medicine|2017Cited by 52
An autosomal dominant neurological disorder caused by de novo variants in FAR1 resulting in uncontrolled synthesis of ether lipidsSacha Ferdinandusse, Paolo Moretti, Kirsty McWalter et al.|Genetics in Medicine|2020Cited by 49
Clinical sites of the Undiagnosed Diseases Network: unique contributions to genomic medicine and scienceKelly Schoch, Jennifer E. Posey, Cecilia Esteves et al.|Genetics in Medicine|2020Cited by 42
<i>SPTSSA</i> variants alter sphingolipid synthesis and cause a complex hereditary spastic paraplegiaSiddharth Srivastava, Tiphanie P. Vogel, Hagar Mor Shaked et al.|Brain|2023Cited by 34